United States Asthma Drugs Market Insight
Published: 10 June 2026 | Report Format: Electronic (PDF)
The United States Asthma Drugs Market is projected to grow at a CAGR of around 5.8%, driven by rising asthma prevalence, increasing adoption of biologic therapies, growing healthcare expenditure, expanding awareness regarding respiratory disease management, and continuous innovation in inhalation drug delivery technologies.
United States Asthma Drugs Market Forecasts to 2035
- The United States Asthma Drugs Market Size Was Estimated at USD 13.18 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 5.8% from 2025 to 2035.
- The United States Asthma Drugs Market Size is Expected to Reach around USD 23.21 Billion by 2035.
Notable Insights for the United States Asthma Drugs Market
- Segmentation Based on Drug Class, the Inhaled Corticosteroids (ICS), Combination Therapies, and Biologics segments held a dominant position in the United States Asthma Drugs Market in 2025 with nearly 78% share, driven by their proven efficacy in long-term asthma control and severe asthma management.
- Segmentation Based on Distribution Channel, Retail Pharmacies and Hospital Pharmacies collectively accounted for approximately 75% share in 2025, supported by broad prescription accessibility, reimbursement coverage, and increasing utilization of specialty respiratory therapies.
- The market is led by AstraZeneca, GSK, and Sanofi; AstraZeneca reported approximately USD 54.07 billion revenue in FY2025, reinforcing its strong position in respiratory therapeutics, biologic innovation, and advanced asthma treatment solutions.
- GSK generated approximately USD 39.61 billion revenue in FY2025, while Sanofi reported nearly USD 53.44 billion revenue, demonstrating the financial strength of leading companies advancing biologics, inhalation therapies, and respiratory disease management.
Download the eBook (ToC)
Research Methodologies Used to Analyze the United States Asthma Drugs Market
This study employs a combination of primary and secondary research methodologies to analyze the United States Asthma Drugs Market. Primary research includes interviews and discussions with pharmaceutical manufacturers, pulmonologists, respiratory specialists, hospital procurement managers, healthcare providers, regulatory experts, and key industry stakeholders. Secondary research involves company annual reports, government healthcare databases, regulatory publications, industry journals, investor presentations, and market intelligence sources. Market estimations are derived using both top-down and bottom-up approaches, while data triangulation and validation techniques ensure the accuracy and reliability of market forecasts, competitive assessments, and industry trends.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States asthma drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Asthma Drugs Market
• AstraZeneca PLC
• GSK plc
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Amgen Inc.
• Novartis AG
• Boehringer Ingelheim International GmbH
• Viatris Inc.
Recent Developments:
- In August 2025, AstraZeneca PLC launched an expanded respiratory biologic treatment program in the United States, enhancing access to advanced therapies for patients suffering from severe uncontrolled asthma.
- In April 2025, Sanofi S.A. collaborated with Regeneron Pharmaceuticals, Inc. to strengthen commercialization and patient access initiatives for biologic asthma therapies across the United States healthcare market.
Market Segmentation:
United States Asthma Drugs Market, By Drug Class
• Inhaled Corticosteroids (ICS)
• Short-Acting Beta Agonists (SABA)
• Long-Acting Beta Agonists (LABA)
• Leukotriene Modifiers
• Combination Therapies
• Biologics
• Others
United States Asthma Drugs Market, By Route of Administration
• Inhalation
• Oral
• Injectable
United States Asthma Drugs Market, By Disease Severity
• Mild Asthma
• Moderate Asthma
• Severe Asthma
United States Asthma Drugs Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
United States Asthma Drugs Market, By End User
• Hospitals
• Specialty Clinics
• Ambulatory Care Centers
• Homecare Settings
Expert Views:
The United States Asthma Drugs Market is expected to witness substantial growth through 2035, supported by increasing asthma prevalence, growing adoption of biologic therapies, expanding respiratory healthcare investments, and continuous advancements in inhalation drug delivery technologies. Strategic product launches, collaborations, and innovations in precision medicine are anticipated to strengthen treatment outcomes and support long-term market expansion across the United States respiratory therapeutics industry.
Author: Komal and Radhika By Spherical Insights and Consulting